BeiGene Is Keeping The Faith In IO/IO Combinations
Part 2 of 2
Global head of R&D Lai Wang talked to Scrip about his expectations for a PD-1/TIGIT combination and remaining confident about the potential of IO/IO combinations in cancer despite disappointments.
